This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by HALL, K. Articles by ÖFVERHOLM, U. Search for Related Content PubMed PubMed Citation Articles by HALL, K. Articles by ÖFVERHOLM, U.

Somatomedin Levels in Pregnancy: Longitudinal Study in Healthy Subjects and Patients with Growth Hormone Deficiency^*

Departments of Endocrinology and Pediatrics Karolinska Hospital, Stockholm, Sweden Rikshospitalet, Oslo, Norway
Departments ofGynecology Rikshospitalet, Oslo, Norway
Pediatrics Rikshospitalet, Oslo, Norway
Department of Psychiatry St Gorans Hospital, Stockholm, Sweden

Address all correspondence and requests for reprints to: K. Hall, Department of Endocrinology, Karolinska Hospital, S-104 01 Stockholm, Sweden.

Somatomedin (Sm) levels throughout pregnancy were determined in a longitudinal study of four normal women and three patients with GH deficiency by use of the RIA for Sm-A, a newly developed RIA for insulin-like growth factor 2 (IGF-2), and the placenta RRA for Sm-A. In both normal women and those with GH deficiency, there was a continuous rise of immunoreactive Sm-A throughout pregnancy. During the third trimester the levels were 2-fold elevated above the level in nonpregnant age-matched normal subjects. No change of immunoreactive IGF-2 levels was found in the normal pregnant women, whereas an increase from low to normal levels was found in GH-deficient patients during pregnancy. The placenta RRA-Sm-A did not detect the increase of Sm-A immunoactivity in the normal pregnant women, whereas the levels were normalized in GH-deficient patients. After delivery a rapid fall of Sm levels occurred in patients with GH deficiency. The calculated halflives for immunoreactive Sm-A and IGF-2 were 27 and 52 h, respectively. The birth weights of the seven children were significantly (P < 0.05) correlated to both the individual peak and the mean maternal value of immunoreactive Sm-A during the last trimester.

The present findings indicate that the production of both IGF-1 and IGF-2 related peptides during pregnancy is independent of maternal pituitary GH production.

^* This work was supported by Grant 4224 from the Swedish Medical Research Council.

Received December 30, 1983.

This article has been cited by other articles:

				X. Yan, L. D. Payet, R. C. Baxter, and S. M. Firth Activity of Human Pregnancy Insulin-Like Growth Factor Binding Protein-3: Determination by Reconstituting Recombinant Complexes Endocrinology, November 1, 2009; 150(11): 4968 - 4976. [Abstract] [Full Text] [PDF]

				A. Lukanova, P. Toniolo, A. Zeleniuch-Jacquotte, K. Grankvist, M. Wulff, A. A. Arslan, Y. Afanasyeva, R. Johansson, P. Lenner, G. Hallmans, et al. Insulin-like Growth Factor I in Pregnancy and Maternal Risk of Breast Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2489 - 2493. [Abstract] [Full Text] [PDF]

				J. Fuglsang, F. Lauszus, A. Flyvbjerg, and P. Ovesen Erratum J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 5042 - 5042. [Abstract] [Full Text] [PDF]

				J. Fuglsang, F. Lauszus, A. Flyvbjerg, and P. Ovesen Human Placental Growth Hormone, Insulin-Like Growth Factor I and -II, and Insulin Requirements during Pregnancy in Type 1 Diabetes J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4355 - 4361. [Abstract] [Full Text] [PDF]

				M. S. Boyne, M. Thame, F. I. Bennett, C. Osmond, J. P. Miell, and T. E. Forrester The Relationship among Circulating Insulin-Like Growth Factor (IGF)-I, IGF-Binding Proteins-1 and -2, and Birth Anthropometry: A Prospective Study J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1687 - 1691. [Abstract] [Full Text] [PDF]

				F. M. Reis, D. D'Antona, and F. Petraglia Predictive Value of Hormone Measurements in Maternal and Fetal Complications of Pregnancy Endocr. Rev., April 1, 2002; 23(2): 230 - 257. [Abstract] [Full Text] [PDF]

				R.P. Holmes, J.M.P. Holly, and P.W. Soothill Maternal serum insulin-like growth factor binding protein-2 and -3 and fetal growth Hum. Reprod., July 1, 1999; 14(7): 1879 - 1884. [Abstract] [Full Text] [PDF]

				J. P. Miell, K. S. Langford, J. S. Jones, P. Noble, M. Westwood, A. White, and K. H. Nicolaides The Maternal Insulin-Like Growth Factor (IGF) and IGF-Binding Protein Response to Trisomic Pregnancy during the First Trimester: A Possible Diagnostic Tool for Trisomy 18 Pregnancies J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 287 - 292. [Abstract] [Full Text] [PDF]